Incidence and Survival Rates among Pediatric Osteogenic Sarcoma Cases in Khon Kaen, Thailand, 1985-2010

  • Published : 2012.09.30


Background: Osteosarcoma is the most common bone cancer in children, responsible for a high rate of amputation and death. This is the first long-term, population-based, epidemiologic and survival study in Thailand. Objective: To study the incidence and survival rates of pediatric osteosarcoma in Khon Kaen. Method: Childhood osteosarcoma cases (0-19 years) diagnosed between 1985-2010 were reviewed. The data were retrieved from the population-based data set of the Khon Kaen Cancer Registry and medical records from Srinagarind Hospital, Faculty of Medicine, Khon Kaen University. All cases were censored until the end of April 2012. The age-standardized incidence rate (ASR) was calculated using the standard method. Survival experience was analyzed using the standard survival function (STATA 9.0) and presented with a Kaplan-Meier curve. Results: 58 cases were enrolled. The overall ASR was 14.1 per million. Males and females were equally affected. The peak incidence was for 15-19 year-olds in both sexes (ASR=10.4 per million in males and 8.5 in females). The 5-year overall survival rate was 27.6% (95% CI: 15.8-40.8%). The median survival time was 1.6 years (95% CI: 1.2-2.1). In a subgroup analysis, the patients who received only chemotherapy survived longer (5-year survival 45.7%, median survival time 4.1 years, p=0.12). Conclusion: The incidence rate for childhood osteosarcoma was slightly less than those reported for Western countries. The survival rate was also lower than reports from developed countries. Further evaluation of the treatment protocol and risk factor stratification is needed.



  1. Allison D, Carney S, Ahlmann E, et al (2012). A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma, doi: 10.1155/2012/704872.
  2. Davis AM, Bell RS, Goodwin PJ (1994). Prognostic factors in osteosarcoma: a critical review. J Clin Oncol, 12, 423-31.
  3. Daw NC, Santana VM, Neel MD, et al (2011). Frontline treatment of localized osteosarcoma without methotrexate: Results of the St. Jude Children's Research Hospital OS99 Trial. Cancer, 117, 2770-8.
  4. Meyers PA, Schwartz CL, Krailo M, et al (2005). Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol, 23, 2004-11.
  5. Mirabello L, Troisi RJ, Savage SA (2009). International osteosarcoma incidence patterns in children and adolescents, middle ages, and elderly persons. Int J Cancer, 125, 229-34.
  6. Mirabello L, Troisi RJ, Savage SA (2009). Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer, 115, 1531-43.
  7. Thailand National Statistical Office (2003). Statistical data bank and information dissemination division. The 2000 population and housing census. Office of Prime Minister.
  8. Parkin DM, Kramarova E, Draper GJ, et al (1998). International incidence of childhood cancer. Vol. 2. IARC Scientific Publication, 144.
  9. Picci P, Mercuri M, Ferrari S, et al (2010). Survival in highgrade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol, 21, 1366-73.
  10. Ries LAG, Smith MA, Gurney JG, et al (1999). Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995, National cancer institute. NIH Pub. No. 99-4649.
  11. Wiangnon S, Veerakul G, Nuchprayoon I, et al (2011). Childhood cancer incidence and survival 2003-2005, Thailand: Study from the Thai Pediatric Oncology Group. Asian Pac J Cancer Prev, 12, 2215-20.

Cited by

  1. Carboplatin and Doxorubicin in Treatment of Pediatric Osteosarcoma: A 9-year Single Institute Experience in the Northern Region of Thailand vol.14, pp.2, 2013,
  2. Benzochloroporphyrin Derivative Induced Cytotoxicity and Inhibition of Tumor Recurrence During Photodynamic Therapy for Osteosarcoma vol.14, pp.5, 2013,
  3. Overview of Cancer Registration Research in the Asian Pacific from 2008-2013 vol.14, pp.8, 2013,
  4. Comparative Outcome of Thai Pediatric Osteosarcoma Treated with Two Protocols: the Role of High-Dose Methotrexate (HDMTX) in a Single Institute Experience vol.15, pp.22, 2014,
  5. Epidemiological Aspects of Osteosarcoma, Giant Cell Tumor and Chondrosarcoma Musculoskeletal Tumors - Experience of the National Rehabilitation Institute, Mexico City vol.16, pp.15, 2015,
  6. Are outcomes in Indian patients different? pp.00224790, 2017,